Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension
Pulmonary Circulation · 2026-10 · 16 (4)
DOI: 10.1002/pul2.70454 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pulmonary Circulation, online erschienen am 12.11.2026. Verfasst von Graham Stockdale und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Critical Care Medicine Integrated Hospital-Care Institute, Cleveland Clinic Cleveland Ohio USA. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Sotatercept, a first‐in‐class activin signaling inhibitor, improves pulmonary vascular hemodynamics and clinical outcomes in pulmonary arterial hypertension (PAH). However, despite reductions in mean pulmonary arterial pressure (mPAP) and pulmonary vascular resistance (PVR), cardiac output (CO) does not generally increase, and some patients experience a decline in CO, a finding of unclear clinical significance. We sought to characterize the heterogeneity of CO responses to sotatercept in PAH and to determine whether incorporating oxygen delivery (DO 2 ) provides additional insight into the physiological significance of these changes. We retrospectively analyzed PAH patients who underwent right heart catheterization before and during sotatercept therapy (median 7.3 months, IQR 4.8, 9.3). Hemodynamic, echocardiographic, hematologic, and clinical parameters were collected, including functional class, 6‐min walk distance (6MWD) and N‐terminal pro‐B‐type natriuretic peptide (NT‐proBNP). Patients were dichotomized by CO response (decreased vs. maintained), and DO 2 was calculated at each catheterization. A total of 56 patients were included. While most demonstrated reductions in PVR and mPAP, 63% experienced decreased CO. Improvements in 6MWD and NT‐proBNP were similar between groups, and hemoglobin increased comparably. However, among patients with decreased CO, 63% had a concomitant decline in DO 2 accompanied by worsening 6MWD and a reduced NT‐proBNP response. In this real‐world cohort, over half of sotatercept‐treated PAH patients experienced reduced CO despite overall hemodynamic and clinical improvement. Concomitant reductions in DO 2 identify a subgroup with worse functional outcomes. These findings suggest that DO 2 adds additional information beyond CO alone when assessing the physiological response to sotatercept.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pulmonary and Critical Care Medicine Integrated Hospital-Care Institute, Cleveland Clinic Cleveland Ohio USA.
- Department of Inflammation and Immunity Cleveland Clinic Research, Cleveland Clinic Cleveland Ohio USA.
- Department of Quantitative Health Sciences Lerner Research Institute, Cleveland Clinic Cleveland Ohio USA.
ORCID-Profile: Graham Stockdale, Adriano R Tonelli, Matthew T Siuba, Pradhab Kirupaharan, Neal F Chaisson, Kristin Highland, Yifan Wang, Gustavo Heresi, Samar Farha
Zitieren
APA
Stockdale, G., Tonelli, A. R., Goyanes, A., Siuba, M. T., Kirupaharan, P., Chaisson, N. F., Highland, K., Parambil, J., Wang, Y., Heresi, G., & Farha, S. (2026). Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension. Pulmonary Circulation, 16(4). https://doi.org/10.1002/pul2.70454
Vancouver
Stockdale G, Tonelli AR, Goyanes A, Siuba MT, Kirupaharan P, Chaisson NF, et al. Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension. Pulmonary Circulation. 2026;16(4). doi:10.1002/pul2.70454
BibTeX
@article{Stockdale2026,
author = {Stockdale, Graham and Tonelli, Adriano R and Goyanes, Alice and Siuba, Matthew T and Kirupaharan, Pradhab and Chaisson, Neal F and Highland, Kristin and Parambil, Joseph and Wang, Yifan and Heresi, Gustavo and Farha, Samar},
title = {Cardiac Output and Oxygen Delivery Responses to Sotatercept in Pulmonary Arterial Hypertension},
journal = {Pulmonary Circulation},
year = {2026},
volume = {16},
number = {4},
doi = {10.1002/pul2.70454}
}
EUVIMED